Stay updated on CV301-Nivolumab Combo in Metastatic CRC Clinical Trial
Sign up to get notified when there's something new on the CV301-Nivolumab Combo in Metastatic CRC Clinical Trial page.

Latest updates to the CV301-Nivolumab Combo in Metastatic CRC Clinical Trial page
- Check4 days agoChange DetectedRevision updated to v3.0.2; the previous v3.0.1 revision tag and the 'Back to Top' element were removed.SummaryDifference0.1%
- Check11 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1.SummaryDifference0.1%
- Check18 days agoChange DetectedThe web page has undergone significant updates, including the addition of a facility name and location, as well as detailed information on various medical topics such as colorectal cancer and specific vaccines. Notably, the revision number has been updated to v3.0.0.SummaryDifference2%
- Check26 days agoNo Change Detected
- Check33 days agoChange DetectedThe web page has been updated from version 2.16.11 to version 2.16.12.SummaryDifference0.1%
- Check40 days agoChange DetectedThe web page has been significantly updated to include extensive details about a clinical trial, including information on study design, eligibility criteria, and treatment protocols. Key entities such as the U.S. Food and Drug Administration (FDA) and the U.S. Agency for Healthcare Research and Quality (AHRQ) have been mentioned, enhancing the credibility and context of the study.SummaryDifference100%
- Check54 days agoChange DetectedThe web page has removed a significant service alert regarding planned maintenance that would affect service availability for over 24 hours, as well as various details about a clinical trial for metastatic colorectal cancer, including study design, eligibility criteria, and treatment protocols.SummaryDifference99%
Stay in the know with updates to CV301-Nivolumab Combo in Metastatic CRC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the CV301-Nivolumab Combo in Metastatic CRC Clinical Trial page.